[{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BRAZIL","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eurofarma Laboratorios S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Undisclosed"},{"orgOrder":0,"company":"Tetec AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"GERMANY","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Matrix-Associated Autologous Chondrocytes","moa":"Autologous chondrocytes","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Tetec AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Tetec AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tetec AG \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"OMS103HP-S","moa":"Bacterial cell membrane","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Seikagaku","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"JAPAN","productType":"Enzyme","year":"2013","type":"Inapplicable","leadProduct":"Condoliase","moa":"Chondroitin-6-sulfate | Hyaluronic acid","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Seikagaku","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seikagaku \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seikagaku \/ Undisclosed"},{"orgOrder":0,"company":"Seikagaku","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"JAPAN","productType":"Enzyme","year":"2015","type":"Inapplicable","leadProduct":"Condoliase","moa":"Chondroitin-6-sulfate | Hyaluronic acid","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Seikagaku","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seikagaku \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seikagaku \/ Undisclosed"},{"orgOrder":0,"company":"Seikagaku","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"JAPAN","productType":"Enzyme","year":"2018","type":"Inapplicable","leadProduct":"SI-6603","moa":"Chondroitin-6-sulfate | Hyaluronic acid","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Seikagaku","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seikagaku \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seikagaku \/ Undisclosed"},{"orgOrder":0,"company":"Anika Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Anika Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Anika Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anika Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Strategic Science & Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Strategic Science & Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Cream","sponsorNew":"Strategic Science & Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Strategic Science & Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"IRELAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Diclofenac Epolamine","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Patch","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Diclofenac Sodium","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Diclofenac Sodium","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Teikoku Seiyaku","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Esflurbiprofen","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Teikoku Seiyaku","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Teikoku Seiyaku \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teikoku Seiyaku \/ Undisclosed"},{"orgOrder":0,"company":"Teikoku Seiyaku","sponsor":"CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services | Clinsearch GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Esflurbiprofen","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Teikoku Seiyaku","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teikoku Seiyaku \/ CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services | Clinsearch GmbH","highestDevelopmentStatusID":"10","companyTruncated":"Teikoku Seiyaku \/ CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services | Clinsearch GmbH"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Gel","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"MedRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Etodolac","moa":"Cyclooxygenase-2","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"MedRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Patch","sponsorNew":"MedRx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MedRx \/ Undisclosed"},{"orgOrder":0,"company":"MedRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Etodolac","moa":"Cyclooxygenase-2","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"MedRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Patch","sponsorNew":"MedRx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MedRx \/ Undisclosed"},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"Radiometer Medical ApS","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Oxygen","moa":"Cytochrome c oxidase subunit 1; NADPH oxidase 1","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nantes University Hospital \/ Radiometer Medical ApS","highestDevelopmentStatusID":"10","companyTruncated":"Nantes University Hospital \/ Radiometer Medical ApS"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Rexlemestrocel-L","moa":"estrogens","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Rexlemestrocel-L","moa":"estrogens","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mesoblast \/ Quintiles Inc","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Quintiles Inc"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Butylated Hydroxyanisole","moa":"Free radical","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Carmell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Carmell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Butylated Hydroxyanisole","moa":"Free radical","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Carmell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Carmell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"GERMANY","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Physician Services Incorporated | Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CANADA","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Teriparatide","moa":"Parathyroid hormone receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"University Health Network, Toronto \/ Physician Services Incorporated | Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"University Health Network, Toronto \/ Physician Services Incorporated | Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Teriparatide","moa":"Parathyroid hormone receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Teriparatide","moa":"Parathyroid hormone receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Basque Health Service","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SPAIN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Basque Health Service","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basque Health Service \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Basque Health Service \/ Undisclosed"},{"orgOrder":0,"company":"Exela Pharma Sciences, LLC.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Exela Pharma Sciences, LLC.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Exela Pharma Sciences, LLC. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Exela Pharma Sciences, LLC. \/ Undisclosed"},{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Santa Casa de S\u00e3o Paulo | Servi\u00e7o Social da Ind\u00fastria do Papel","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BRAZIL","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Santa Casa de S\u00e3o Paulo | Servi\u00e7o Social da Ind\u00fastria do Papel","highestDevelopmentStatusID":"10","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Santa Casa de S\u00e3o Paulo | Servi\u00e7o Social da Ind\u00fastria do Papel"},{"orgOrder":0,"company":"Ensol BioSciences","sponsor":"Spine BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"SB-01","moa":"TGF-beta-1","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Ensol BioSciences","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0.16,"dosageForm":"Undisclosed","sponsorNew":"Ensol BioSciences \/ Spine BioPharma","highestDevelopmentStatusID":"10","companyTruncated":"Ensol BioSciences \/ Spine BioPharma"},{"orgOrder":0,"company":"Spine BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SB-01","moa":"TGF-beta-1","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Spine BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spine BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spine BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Amgen Inc"},{"orgOrder":0,"company":"Angitia Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"AGA111","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Angitia Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Angitia Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Angitia Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Angitia Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AGA111","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Angitia Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Angitia Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Angitia Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Angitia Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"AGA111","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Angitia Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Angitia Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Angitia Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hyundai Bioland","sponsor":"Medipost","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Hyundai Bioland","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hyundai Bioland \/ Medipost","highestDevelopmentStatusID":"10","companyTruncated":"Hyundai Bioland \/ Medipost"},{"orgOrder":0,"company":"Histogenics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"Autologous Cartilagenous Tissue","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Histogenics Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Histogenics Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Histogenics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"OrthoCellix","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Merger","leadProduct":"Autologous Cartilagenous Tissue","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"OrthoCellix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"OrthoCellix \/ Carisma Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"OrthoCellix \/ Carisma Therapeutics"},{"orgOrder":0,"company":"Tetec AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Autologous Chondrocyte","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Tetec AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Tetec AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tetec AG \/ Undisclosed"},{"orgOrder":0,"company":"The University of Western Australia","sponsor":"Arthrex","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"AUSTRALIA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Autologous Conditioned Plasma","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"The University of Western Australia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"The University of Western Australia \/ Arthrex","highestDevelopmentStatusID":"10","companyTruncated":"The University of Western Australia \/ Arthrex"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Autologous Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pluri","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Mesenchymal-Like Adherent Stromal Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pluri \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pluri \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"Nutritional Supplement","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Heel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Traumeel","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Heel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Gel","sponsorNew":"Heel \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Heel \/ Undisclosed"},{"orgOrder":0,"company":"Heel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Traumeel","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Heel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Heel \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Heel \/ Undisclosed"},{"orgOrder":0,"company":"McMaster University","sponsor":"Canadian Institutes of Health Research | McMaster Surgical Associates | Hamilton Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McMaster University \/ Canadian Institutes of Health Research | McMaster Surgical Associates | Hamilton Health Sciences","highestDevelopmentStatusID":"10","companyTruncated":"McMaster University \/ Canadian Institutes of Health Research | McMaster Surgical Associates | Hamilton Health Sciences"},{"orgOrder":0,"company":"University of Miami","sponsor":"Arthrex","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Miami \/ Arthrex","highestDevelopmentStatusID":"10","companyTruncated":"University of Miami \/ Arthrex"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
